跳至主要内容
临床试验/NCT01997658
NCT01997658已完成2 期

Preoperative Glucocorticoid Use in Major Hepatectomy - A Randomized Controlled Trial

University of Calgary1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2014年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
200
试验地点
1
主要终点
Total Complication rate

研究概览

简要总结

Background: Reducing postoperative complications remains a dominant challenge for all clinicians. By minimizing the incidence of adverse outcomes, health care costs and patient recovery can be improved. A number of studies have documented that fewer postoperative adverse events occur with the preoperative use of glucocorticoids (GC). Two small manuscripts support the use of GC with particular reference to liver resection.

Major hepatectomy can be associated with numerous adverse outcomes (hemorrhage, bile leak, liver failure, wound infection other infectious complications). This rate approaches 54% in some trials. Additionally, the liver is responsible for numerous metabolic functions and actively participates in the acute phase response via the generation of inflammatory mediators and cytokines. Glucocorticoids play an important role in suppressing the over-synthesis of pro-inflammatory cytokines and therefore may assist in reducing postoperative complications. These pro-inflammatory cytokines recruit leukocytes at the site of injury, leading to hepatic parenchymal cell damage. Decreasing pro-inflammatory cytokine ratio may therefore reduce hepatic damage.

Methods: The investigators will complete a randomized controlled trial evaluating the incidence of postoperative complications and overall hospital length of stay in adult patients following preoperative vs. no administration of 500 mg of methylprednisolone (MP) within 30 minutes of starting a hepatectomy. This trial will employ block randomization and intention to treat protocols. Four HPB surgeons at University of Calgary will participate in the trial with a planned inclusion of all patients scheduled to undergo hepatectomy in a period of 2 years.

Analysis: Standard statistical analysis will include normally or near-normally distributed variables reported as means and non-normally distributed variables as medians. Means will be compared using the student's t test and medians using the Mann-Whitney U test. Differences in proportions among categorical data will be assessed using Fischer's exact test. A p value < 0.05 will represent statistical significance for all comparisons.

Hypothesis: Preoperative GC administration will decrease the incidence of postoperative complications and overall hospital length of stay following hepatectomy.

Potential Impact: Health care utilization and economics are an expanding area of importance. Reducing post-hepatectomy complications are crucial to this end.

详细描述

Introduction:

Major hepatectomy lead to significant postoperative anatomical and physiological changes. The liver dictates the systemic metabolic environment and helps maintain homeostasis. When segments of liver are removed, it is challenged to regenerate and restore cellular volume, as well as continuing to perform mandated metabolic functions. Major hepatectomy can result in multiple complications (hemorrhage, biliary fistulae, wound infection, liver failure) with an overall complication rate up to 54% in some studies.

Recent studies purport that preoperative administration of GC may suppress the acute phase response during the early postoperative period. GCs are steroid hormones with a variety of immunological and biochemical functions (anti-inflammatory attenuation of the acute phase response by binding to intra-cytoplasmic GC receptors and therefore increased transcription of anti-inflammatory proteins interleukin-10 (IL-10), IL-1-receptor antagonist (IL-Ra), lipocortin-1 and neutral endopeptidase, or direct inhibition of activated transcription factors (nuclear factor kB, activator protein-1)). GC can also suppress gene expression by altering the chromatin structure and tightening DNA coils.

The acute phase response is a neuro-humoral and time-limited defensive mechanism, which aims to restore homeostasis. It is characterized by fever, leukocytosis, gluconeogenesis, as well as changes in lipid, carbohydrate and protein metabolism. Activation of the hypothalamus-pituitary-adrenal axis, coagulation and compliment pathways is also one of the salient features of the acute phase response. It is regulated by cytokine receptor antagonists (IL-1Ra) and soluble cytokine receptors. Cytokines are soluble, low molecular weight glycoproteins that act as inflammatory mediators and can be broadly divided into pro and anti-inflammatory cytokines. At low concentrations, they have a paracrine effect, while in high concentrations they act systemically. These pro-inflammatory cytokines (IL-1, IL-2, IL-6 and tumor necrosis factor (TNF) alpha) remain in the plasma for at least 24 hours after generation. They also attract leukocytes (neutrophils and macrophages) to the site of injury and are detrimental if produced in large amounts. Oka et al have demonstrated that increasing levels of IL-6 are directly related to an increased rate of postoperative complications.

In low doses, GC reduce short term mortality, reverse the shock process and improve hemodynamics in septic shock patients. In a meta-analysis of 17 RCTs, Annane et al found that 28-day mortality for a low-dose dexamethasone (DXA) group, versus control group was 35.3% vs. 38.5%. Shock reversal was also increased in the DXA group (66.9% vs. 58.6%) and the ICU stay was decreased by 4.49 days.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Elective surgery patients (adults) scheduled to undergo hepatectomy at FMC from May 2013 to May 2015.

排除标准

  • Patients will be excluded if they are unable to give informed consent.

研究组 & 干预措施

Methylprednisolone

Experimental

Injection, 500 mg, single use, over 15 to 20 minutes.

干预措施: Methylprednisolone (Drug)

Control

Placebo Comparator

In Control arm, patients will receive the standardized surgical treatment without receiving methylprednisolone preoperatively (placebo).

干预措施: Placebo (Drug)

结局指标

主要结局

Total Complication rate

时间窗: 1 month

次要结局

  • Total length of hospital stay(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Chad G. Ball

Assistant Professor

University of Calgary

研究点 (1)

Loading locations...

相似试验